• Linkedin
  • Twitter
  • Pinterest
  • Vimeo
  • Skype
  • Gplus
  • Youtube
  • Rss
  • Home
  • Events
  • Careers at CAPTIS
  • Log In / Sign In ▼
    • Log In with LinkedIn
    • Register w/out LinkedIn
    • Login w/out LinkedIn
    • Reset Lost Password
  • 🔒 MEMBER AREA ▼
    • View your profile
    • Edit your profile
    • Log out
       ☎ US Offices 1 (800) 445-1839 Toll Free | Europe/Int'l +41 22 518 2100
CAPTIS Executive Search
  • Home
  • You are a Business
    • Executive Search
    • Our Commitments
    • Other Services
    • Our Locations
    • About Us
    • Key Values
  • You are a Healthcare Executive
    • Dealing with CAPTIS
    • Candidate Contact Form
    • Login with LinkedIn
    • Create an Account
    • Log in (Existing Account)
    • WW Trade Shows
      • Medical & Pharmaceutical
      • Orthopedics
      • Spine
      • Cardiovascular
      • Diagnostics
      • Wound Care
      • Plastic & Aesthetic Surgery
      • Surgery
      • Trauma
      • Pediatric Care
    • Industry News
      • News
      • Wall Street Beat
      • Business/Financial News
      • Clinical Trials
      • Musculoskeletal News Roundup
      • Cardiovascular
      • M&A Activity
      • Food & Drug Administration (FDA)
      • Wound Care
      • Practice Management
  • CAPTIS Magazine
    • Healthcare News
    • @CaptisCorp Twitter Timeline
    • Healthcare Events
    • CAPTIS LinkedIn Timeline
    • Articles ➜
      • Recruiting
      • Personal Development
      • News
  • Make an Inquiry
  • Contact Us
    • General Contact Form
    • Healthcare Executive Contact
    • Apply for a position at CAPTIS
    • Call 1 800 445 1839
      (Cell/Mobile US & Canada Toll Free, or Skype)
    • Call +41 22 518 2100
      (Cell/Mobile Swiss Landline Switchboard, or Skype)
  • Search
  • Menu

Captare. Aestimare. Eligere. Succedere.

CAPTIS – Your Global Healthcare & MedTech Executive Search Provider

You are a Business

You are an Executive

Want to work at CAPTIS

Learn about our services

 

 

Executive Search
Submit an inquiry

GET HEADHUNTED!

Create and/or update

your confidential profile

 

Healthcare Executive General Information
Create an account & Add your profile

Go to our Careers page

 

 

 

 

 

CAPTIS Careers

Recent Healthcare News:

07/22/2019/by CAPTIS

Rising Pharmaceuticals announces the US launch of generic version of Pregabalin Capsules

Pregabalin Capsules had U.S. sales of approximately $5,497 million…
07/22/2019/by CAPTIS

Novartis multiple sclerosis product Gilenya approved in China

07/22/2019/by CAPTIS

Celgene gets FDA approval for Otezla to treat oral ulcers associated with Behçet’s Disease

07/19/2019/by CAPTIS

Transgene receives MHRA approval for clinical trial of next-generation oncolytic virus

07/19/2019/by CAPTIS

LifeMax receives rare pediatric disease designation for LM-030 to treat Netherton Syndrome

07/19/2019/by CAPTIS

Boehringer, Bridge Biotherapeutics sign licence agreement for IPF treatment candidate

07/19/2019/by CAPTIS

Astellas signs licensing deal for Frequency’s regenerative drug FX-322

07/18/2019/by CAPTIS

AHF calls on Gilead to set up fund for victims harmed by its TDF-based drugs

07/18/2019/by CAPTIS

PureTech acquires new clinical-stage programme LYT-100 to treat lymphedema

07/18/2019/by CAPTIS

FDA approves Merck’s Recarbrio to treat complicated infections

07/17/2019/by CAPTIS

Kite to bolster cell therapy manufacturing capabilities with new viral vector facility

The new site builds on Kite’s existing state-of-the-art…
07/17/2019/by CAPTIS

AbbVie enhances early stage oncology pipeline with acquisition of Mavupharma

07/17/2019/by CAPTIS

Novartis’ crizanlizumab secures FDA priority review for sickle cell disease

07/17/2019/by CAPTIS

GSK’s Zejula meets primary endpoint in phase 3 ovarian cancer trial

07/16/2019/by CAPTIS

Recordati to acquire worldwide rights to Signifor and Osilodrostat

07/16/2019/by CAPTIS

AstraZeneca’s Imfinzi gets FDA orphan drug status for small cell lung cancer

07/16/2019/by CAPTIS

Dicerna gets breakthrough therapy designation for DCR-PHXC to treat primary hyperoxaluria type 1

07/16/2019/by CAPTIS

Boehringer Ingelheim buys Swiss biotech firm AMAL Therapeutics

07/15/2019/by CAPTIS

Sun Pharma launches Ezallor Sprinkle in US for people who have difficulty swallowing

07/15/2019/by CAPTIS

Sensorion receives FDA IND approval for Arazasetron

Go to the Healthcare News

Recent news from your industry: Finance, M&A, Products, Companies and more…

Upcoming Events:

We Suggest:

Gilead, Galapagos sign 10-year research and development deal

0 Comments
/
07/15/2019
As per terms of the deal, Galapagos will secure $3.95bn (£3.5bn)…
Read more
https://www.captis.com/wp-content/uploads/2017/02/004.jpg 450 900 CAPTIS https://www.captis.com/wp-content/uploads/2016/11/logo_transp_top_final.png CAPTIS2019-07-15 00:40:192019-07-15 00:40:19Gilead, Galapagos sign 10-year research and development deal

Gilead, Renown Institute for Health Innovation announce collaboration to advance understanding of NASH

0 Comments
/
07/12/2019
Under the terms of the collaboration and license agreement, Gilead…
Read more
https://www.captis.com/wp-content/uploads/2017/02/004.jpg 450 900 CAPTIS https://www.captis.com/wp-content/uploads/2016/11/logo_transp_top_final.png CAPTIS2019-07-12 03:01:192019-07-12 03:01:28Gilead, Renown Institute for Health Innovation announce collaboration to advance understanding of NASH

SOTIO initiates first-in-human clinical trial with IL-15 superagonist SO-C101

0 Comments
/
07/12/2019
The phase I/Ib study (SC103) will evaluate the safety and preliminary…
Read more
https://www.captis.com/wp-content/uploads/2017/02/004.jpg 450 900 CAPTIS https://www.captis.com/wp-content/uploads/2016/11/logo_transp_top_final.png CAPTIS2019-07-12 01:31:162019-07-12 01:31:26SOTIO initiates first-in-human clinical trial with IL-15 superagonist SO-C101

Novartis, Amgen halt Alzheimer’s clinical programme with BACE1 inhibitor

0 Comments
/
07/12/2019
The partnership will discontinue the evaluation of CNP520 in…
Read more
https://www.captis.com/wp-content/uploads/2017/02/004.jpg 450 900 CAPTIS https://www.captis.com/wp-content/uploads/2016/11/logo_transp_top_final.png CAPTIS2019-07-12 00:01:242019-07-12 00:01:41Novartis, Amgen halt Alzheimer’s clinical programme with BACE1 inhibitor

ViiV Healthcare’s phase 3 study of dolutegravir plus lamivudine meets primary endpoint

0 Comments
/
07/11/2019
The TANGO study was conducted to assess whether adults living…
Read more
https://www.captis.com/wp-content/uploads/2017/02/004.jpg 450 900 CAPTIS https://www.captis.com/wp-content/uploads/2016/11/logo_transp_top_final.png CAPTIS2019-07-11 03:01:392019-07-11 03:01:50ViiV Healthcare’s phase 3 study of dolutegravir plus lamivudine meets primary endpoint

FDA accepts to review Sanofi’s multiple myeloma candidate isatuximab

0 Comments
/
07/11/2019
An investigational monoclonal antibody, isatuximab, has been…
Read more
https://www.captis.com/wp-content/uploads/2017/02/004.jpg 450 900 CAPTIS https://www.captis.com/wp-content/uploads/2016/11/logo_transp_top_final.png CAPTIS2019-07-11 02:31:452019-07-11 02:31:50FDA accepts to review Sanofi’s multiple myeloma candidate isatuximab

Jazz Pharmaceuticals acquires pre-clinical pan-RAF inhibitor program from Redx Pharma

0 Comments
/
07/11/2019
Redx will perform certain pre-clinical activities for the program…
Read more
https://www.captis.com/wp-content/uploads/2017/02/004.jpg 450 900 CAPTIS https://www.captis.com/wp-content/uploads/2016/11/logo_transp_top_final.png CAPTIS2019-07-11 00:31:592019-07-11 00:32:01Jazz Pharmaceuticals acquires pre-clinical pan-RAF inhibitor program from Redx Pharma

Nexus Pharmaceuticals to build sterile injectable production facility in Wisconsin

0 Comments
/
07/11/2019
Nexus has entered into an agreement with Wisconsin’s village…
Read more
https://www.captis.com/wp-content/uploads/2017/02/004.jpg 450 900 CAPTIS https://www.captis.com/wp-content/uploads/2016/11/logo_transp_top_final.png CAPTIS2019-07-11 00:01:212019-07-11 00:01:22Nexus Pharmaceuticals to build sterile injectable production facility in Wisconsin

Celsius Therapeutics signs collaboration agreement with Janssen to identify response biomarkers for ulcerative colitis

0 Comments
/
07/10/2019
Under the terms of the agreement, Celsius will apply its proprietary…
Read more
https://www.captis.com/wp-content/uploads/2017/02/004.jpg 450 900 CAPTIS https://www.captis.com/wp-content/uploads/2016/11/logo_transp_top_final.png CAPTIS2019-07-10 04:15:192019-07-10 04:15:20Celsius Therapeutics signs collaboration agreement with Janssen to identify response biomarkers for ulcerative colitis

Lyndra Therapeutics and Gilead Sciences to collaborate on development of ultra-long-acting HIV therapeutics

0 Comments
/
07/10/2019
Gilead will have exclusive rights to Lyndra’s therapeutics…
Read more
https://www.captis.com/wp-content/uploads/2017/02/004.jpg 450 900 CAPTIS https://www.captis.com/wp-content/uploads/2016/11/logo_transp_top_final.png CAPTIS2019-07-10 04:15:162019-07-10 04:15:17Lyndra Therapeutics and Gilead Sciences to collaborate on development of ultra-long-acting HIV therapeutics

Altimmune to buy Presidio Partners portfolio firm Spitfire Pharma

0 Comments
/
07/10/2019
Velocity Pharmaceutical Development, along with Dr John Nestor,…
Read more
https://www.captis.com/wp-content/uploads/2017/02/004.jpg 450 900 CAPTIS https://www.captis.com/wp-content/uploads/2016/11/logo_transp_top_final.png CAPTIS2019-07-10 04:15:132019-07-10 04:15:15Altimmune to buy Presidio Partners portfolio firm Spitfire Pharma

FDA accepts Merck’s sBLA for Keytruda six-week dosing schedule for melanoma and multiple other indications

0 Comments
/
07/10/2019
Merck is seeking FDA approval of a 400 mg Q6W dose infused over…
Read more
https://www.captis.com/wp-content/uploads/2017/02/004.jpg 450 900 CAPTIS https://www.captis.com/wp-content/uploads/2016/11/logo_transp_top_final.png CAPTIS2019-07-10 04:15:092019-07-10 04:15:11FDA accepts Merck’s sBLA for Keytruda six-week dosing schedule for melanoma and multiple other indications

MorphoSys secures option to license Vivoryon’s QPCTL inhibitors for cancer

0 Comments
/
07/10/2019
The option obtained by MorphoSys gives it the rights to globally…
Read more
https://www.captis.com/wp-content/uploads/2017/02/004.jpg 450 900 CAPTIS https://www.captis.com/wp-content/uploads/2016/11/logo_transp_top_final.png CAPTIS2019-07-10 04:15:062019-07-10 04:15:07MorphoSys secures option to license Vivoryon’s QPCTL inhibitors for cancer

ViiV Healthcare begins study on implementation of once-monthly injectable HIV treatment

0 Comments
/
07/10/2019
ViiV Healthcare said that its team will work with clinical staff…
Read more
https://www.captis.com/wp-content/uploads/2017/02/004.jpg 450 900 CAPTIS https://www.captis.com/wp-content/uploads/2016/11/logo_transp_top_final.png CAPTIS2019-07-10 04:15:022019-07-10 04:15:04ViiV Healthcare begins study on implementation of once-monthly injectable HIV treatment

BiondVax enrols first patient in phase 3 second cohort of M-001 flu vaccine

0 Comments
/
07/10/2019
Close to 8,000 participants are being enrolled by BiondVax for…
Read more
https://www.captis.com/wp-content/uploads/2017/02/004.jpg 450 900 CAPTIS https://www.captis.com/wp-content/uploads/2016/11/logo_transp_top_final.png CAPTIS2019-07-10 04:14:592019-07-10 04:15:00BiondVax enrols first patient in phase 3 second cohort of M-001 flu vaccine

PhoreMost, inStem enter structural biology alliance

0 Comments
/
07/10/2019
CCBT at the Institute for Stem Cell Science and Regenerative…
Read more
https://www.captis.com/wp-content/uploads/2017/02/004.jpg 450 900 CAPTIS https://www.captis.com/wp-content/uploads/2016/11/logo_transp_top_final.png CAPTIS2019-07-10 04:14:552019-07-10 04:14:56PhoreMost, inStem enter structural biology alliance

Ipsen, Servier announce initial phase 1/2 data of liposomal irinotecan in metastatic pancreatic cancer

0 Comments
/
07/10/2019
The results, which were presented as a short oral presentation,…
Read more
https://www.captis.com/wp-content/uploads/2017/02/004.jpg 450 900 CAPTIS https://www.captis.com/wp-content/uploads/2016/11/logo_transp_top_final.png CAPTIS2019-07-10 04:14:522019-07-10 04:14:53Ipsen, Servier announce initial phase 1/2 data of liposomal irinotecan in metastatic pancreatic cancer

Fresenius Kabi introduces Levothyroxine Sodium Injection Solution

0 Comments
/
07/10/2019
Fresenius Kabi Levothyroxine Sodium Injection is the first-and-only…
Read more
https://www.captis.com/wp-content/uploads/2017/02/004.jpg 450 900 CAPTIS https://www.captis.com/wp-content/uploads/2016/11/logo_transp_top_final.png CAPTIS2019-07-10 04:14:492019-07-10 04:14:50Fresenius Kabi introduces Levothyroxine Sodium Injection Solution

VALBIOTIS announces positive results from phase IIA trial of VALEDIA in prediabetics

0 Comments
/
07/05/2019
In this population, VALEDIA significantly reduced fasting and…
Read more
https://www.captis.com/wp-content/uploads/2017/02/004.jpg 450 900 CAPTIS https://www.captis.com/wp-content/uploads/2016/11/logo_transp_top_final.png CAPTIS2019-07-05 03:01:262019-07-05 03:01:27VALBIOTIS announces positive results from phase IIA trial of VALEDIA in prediabetics

Cantargia announces full recruitment of CAN04 monotherapy arm in ongoing phase IIa clinical trial

0 Comments
/
07/05/2019
Here, CAN04 is examined as monotherapy or in chemotherapy combinations…
Read more
https://www.captis.com/wp-content/uploads/2017/02/004.jpg 450 900 CAPTIS https://www.captis.com/wp-content/uploads/2016/11/logo_transp_top_final.png CAPTIS2019-07-05 03:01:242019-07-05 03:01:25Cantargia announces full recruitment of CAN04 monotherapy arm in ongoing phase IIa clinical trial
PreviousNext

  • Thorough Network

  • Deep Knowledge

  • Comprehensive Process

  • Ethical Approach

  • Confidentiality

  • Assessment Capacity

99%

Percentage of successful project completion

85%

Of placed executives remain with the client company 3 or more years

  • Share on Facebook
  • Share on Twitter
  • Share on Google+
  • Share on Pinterest
  • Share on Linkedin
  • Share on Tumblr
  • Share on Vk
  • Share on Reddit
  • Share by Mail

News from Twitter

Twitter
Spineway
Spineway
@Spineway1

🎬 Testimonial from Dr. Pablo Gato (Argentina) 🎬 Do you think the Minimal #Invasive #Surgery will trust a large majority of the #spine market in the future? #Spineway #future #surgeon ⏩ bit.ly/2JlOFXT pic.twitter.com/aw7X…

reply retweet favorite
10:30 am · 07/04/2019 ·
Retweeted by CAPTIS
Twitter
BIO International Convention
BIO International Convention
@BIOConvention

Registration in the Grand Hall zipping right along at #BIO2019 this morning! We are looking forward to a great day of Partnering, education and networking. pic.twitter.com/e6Hb…

reply retweet favorite
11:12 am · 06/04/2019 ·
Retweeted by CAPTIS
Twitter
BIO International Convention
BIO International Convention
@BIOConvention

Good morning, Philadelphia! It's officially day 1 of #BIO2019-- here are today's highlights. View the full schedule of today's events in myBIO: bit.ly/2KfZcWp pic.twitter.com/w6uv…

reply retweet favorite
11:11 am · 06/04/2019 ·
Retweeted by CAPTIS
Twitter
Centinel Spine
Centinel Spine
@CentinelSpine

Congratulations to Rory Sabbatini, prodisc® athlete-ambassador, on his 6th place finish at the @CSChallengeFW. Rory and @BrianGayPGA played the green well this weekend—while educating @PGATOUR fans on spinal surgery with prodisc. bit.ly/2W9cUSb #regainyourlife

reply retweet favorite
9:47 pm · 05/28/2019 ·
Retweeted by CAPTIS
Twitter
TranS1
TranS1
@TranS1

I am lucky to work for a company that gives a person the ability to want to make every day count. TranS1 has given me the ability to stop looking back and remember how to live a life - Get back to living! #tuesdayteammember #T14life #lovewhereyouwork #lovewhatyoudo pic.twitter.com/IiCV…

reply retweet favorite
9:47 pm · 05/28/2019 ·
Retweeted by CAPTIS
Twitter
Quantum Genomics
Quantum Genomics
@QuantumGenomics

Nous profitons de la #JournéeMondialeContreLHypertension pour vous rappeler que notre mission est de développer de nouvelles thérapies innovantes pour les besoins médicaux non satisfaits dans le domaine des maladies cardiovasculaires. #Hypertension #Firibastat #QuantumGenomics pic.twitter.com/bELl…

reply retweet favorite
12:12 pm · 05/18/2019 ·
Retweeted by CAPTIS
Twitter
CAPTIS
CAPTIS
@CaptisCorp

Let's meet at #AAOS2019 in Las Vegas. Feel free to make contact. pic.twitter.com/Cybu…

reply retweet favorite
4:11 pm · 03/14/2019
Twitter
Dr. Alfredo Figueiredo
Dr. Alfredo Figueiredo
@AlfredoFig1

#LowBackPain - a good summary by the European Spine Society @EUROSPINESoc eurospinepatientline… #Orthopaedics #SpineSurgery pic.twitter.com/yo6E…

reply retweet favorite
5:05 am · 02/21/2019 ·
Retweeted by CAPTIS
Twitter
CAPTIS
CAPTIS
@CaptisCorp

Happy President's Day from CAPTIS!

reply retweet favorite
5:06 pm · 02/18/2019
Twitter
Medtronic Spine
Medtronic Spine
@Medtronic_Spine

We are saddened to share the news of the passing of Dr. Yves Cotrel. A pioneer in modern spine surgery, Dr. Cotrel's company Sofamor, was the foundation for what would become Medtronic Spine. Dr. Cotrel's contributions will live on for years to come. Condolences to his family. pic.twitter.com/JJ1Z…

reply retweet favorite
5:27 pm · 02/01/2019 ·
Retweeted by CAPTIS
Twitter
Arab Health
Arab Health
@Arab_Health

The 44th edition of Arab Health is officially now open. #ArabHealth2019 runs until the 31st of January 2019 at the Dubai World Trade Centre and the Conrad Dubai from 10 am to 6 pm. Find out more on our website or download the Arab Health 2019 show app: bit.ly/2n3Z5Q pic.twitter.com/oasI…

reply retweet favorite
5:35 pm · 01/29/2019 ·
Retweeted by CAPTIS
Twitter
Novartis Cancer
Novartis Cancer
@NovartisCancer

Cancer is not a ‘one size fits all,’ nor is the way we treat it. We are working to better understand the different ways a cancer can mutate so we can discover new approaches to treat some of the most difficult-to-treat types of the disease. #ReimagineMedicine #ESMO18 pic.twitter.com/41QL…

reply retweet favorite
6:56 pm · 10/24/2018 ·
Retweeted by CAPTIS
Twitter
Epic CV
Epic CV
@Epic_CV

Read carefully employer's directions on how to apply. #resume #resumetips

reply retweet favorite
7:47 am · 10/16/2018 ·
Retweeted by CAPTIS
Twitter
World Spine Care
World Spine Care
@WorldSpineCare

Here are 5 Tips to Avoid Back Pain from #WorldSpineDay. #Exercise #Posture #Stress #HealthyEating #Strength pic.twitter.com/AT1D…

reply retweet favorite
7:46 am · 10/16/2018 ·
Retweeted by CAPTIS
Twitter
Neurochecklists
Neurochecklists
@neurochecklists

Large-vessel giant cell arteritis: diagnosis, monitoring and management | Rheumatology | Oxford Academic academic.oup.com/rhe…

reply retweet favorite
7:40 am · 10/16/2018 ·
Retweeted by CAPTIS
Twitter
Stryker Endoscopy
Stryker Endoscopy
@StrykerEndo

Scientists have made an unexpected discovery while investigating the triggering factors of #ColonCancer: Cell stress in combination with an altered microbiota in the colon drives tumor growth. Learn more: ow.ly/JxtK30meLTY pic.twitter.com/U51Q…

reply retweet favorite
7:39 am · 10/16/2018 ·
Retweeted by CAPTIS
Twitter
Implantech
Implantech
@Implantech

If you are in Dallas attending the AAFPRS 12th International Symposium of Facial Plastic Surgery don’t miss out on this Breakfast Symposium tomorrow morning with Dr. William Binder that is sponsored by Implantech! #implantech #superiorpatientaesthetics #implantechrewards #aafprs pic.twitter.com/HCzK…

reply retweet favorite
7:38 am · 10/16/2018 ·
Retweeted by CAPTIS
Twitter
American College of Cardiology
American College of Cardiology
@ACCinTouch

Less than one month left to submit your science for #ACC19! Abstract & case submissions are due Oct. 16. Learn more: ow.ly/4nyf30lYZxh pic.twitter.com/Mnwv…

reply retweet favorite
4:46 pm · 09/26/2018 ·
Retweeted by CAPTIS
Twitter
Novartis Cancer
Novartis Cancer
@NovartisCancer

With #CARTcell therapy, an inactive virus programs T cells with new genetic information to help recognize specific antigens found on normal cells and certain blood cancer cells. As the CAR-T cells multiply, new copies also gain this ability. #CARTCellStory pic.twitter.com/Xuoh…

reply retweet favorite
4:42 pm · 09/26/2018 ·
Retweeted by CAPTIS
Twitter
Integra LifeSciences
Integra LifeSciences
@integra_life

Make plans to visit the Integra LifeSciences Booth# 919 during Plastic Surgery The Meeting September 28th - October 1st. #Integra_LifeSciences #DurableIsBeautiful #PSTM18 #ASPS #PlasticSurgery pic.twitter.com/8QGv…

reply retweet favorite
4:42 pm · 09/26/2018 ·
Retweeted by CAPTIS
Follow @CaptisCorp

Follow CAPTIS



CAPTIS
Followon TwitterSubscribeto RSS Feed

We Recommend

Our very best and up-to-date selection of healthcare Industries' News (Products, Markets, Companies, R&D, Technology, Opportunities, Investment & Finance...).
Read at Healthcare News

CAPTIS Newsletter

Call CAPTIS

United States Offices
1 (800) 445-1839

(United States & Canada Toll Free)

Europe & International
+41 22 518 2100

© CAPTIS - Executive Search - 2017 - copyright@captis.com
  • Linkedin
  • Twitter
  • Pinterest
  • Vimeo
  • Skype
  • Gplus
  • Youtube
  • Rss
  • Events
  • For Healthcare Executives
  • Legal & Privacy Notes, GDPR & Cookies Policy
  • Client Area
X
Thank you for visiting our new website! Help us improve, let us know your feedback (Anonymous 2 min survey)
Survey
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.OK, got itCookies Policy
Scroll to top